English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Alcohol dependence (AD) is a chronic and recurrent disease that is a major social and clinical problem. The Food and Drug Administration (FDA) has approved a few drugs for AD treatment like disulfiram, naltrexone and acamprosate. Their efficacy is limited and depends on many additional factors. Also therefore, new methods of therapy are still being sought. Currently, research is focused on a new generation of antiepileptic drugs that could improve the efficiency of AD treatment thanks to their multidirectional mechanism of action associated with neurotransmission systems involved in the pathogenesis of addiction. Topiramate is the most widely studied drug in this area. The results of preclinical studies showed that the drug reduces the intake of ethanol and alleviates symptoms of withdrawal syndrome in animals. The results of clinical observations in patients with AD confirmed the efStreszczenie

The efficacy of topiramate in alcohol dependence therapy – current research and prospects of use